Topic: pharma CEO

Perrigo CEO Uwe Roehrhoff is stepping down effective immediately, the company announced, to be replaced by former tobacco executive Murray Kessler.

Hours after Pfizer unveiled its CEO succession plan, industry watchers had one key question: Will incoming chief Albert Bourla chase M&A?

After steering Pfizer through nine years of selloffs, spinoffs, reorgs, drug launches, patent losses, dealmaking—and one big deal that didn’t—CEO Ian Read is stepping aside.

A policy change by the board of Merck & Co. will allow Ken Frazier to remain CEO after he turns 65 next year.

Jackie Fouse has been a prime CEO candidate since leaving Celgene, and it’s Agios that finally gets to claim her as its next skipper.

Though she has spent most of her career in oncology, Deborah Dunsire, M.D., says she doesn't plan to expand Lundbeck outside of neuroscience.

Sanofi's CFO search lasted two months and led the company to a financial executive from French automaker PSA Group.

Now that former shareholders of Sprout have the company back in their hands, they’ve reinstalled a familiar face at the helm.

As Glaxo CEO, Andrew Witty was prepping for a future rife with payer pressure that could hit pharma hard. And now, he'll apply that pressure.

After Lilly CEO David Ricks took over in 2016, he revamped management while cutting costs and jobs—and earned nearly $16 million in pay for his efforts.